Sofinnova Venture Partners X, L.P. 4
4 · Inozyme Pharma, Inc. · Filed Jul 28, 2020
Insider Transaction Report
Form 4
Sofinnova Venture Partners X, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-07-28+1,590,808→ 1,590,808 total - Purchase
Common Stock
2020-07-28$16.00/sh+437,500$7,000,000→ 2,028,308 total - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−11,888,112→ 0 total→ Common Stock (1,590,808 underlying)
Footnotes (2)
- [F1]On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.